Ligand Pharma (LGND) Gains After Retrophin (RTRX) Announces Positive Sparsentan Phase 2 Data

September 7, 2016 7:40 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Ligand Pharma (NASDAQ: LGND) gained Wednesday after Retrophin (Nasdaq: RTRX) announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of FSGS.

Retrophin previously secured a license to sparsentan from Ligand Pharmaceuticals and Bristol-Myers Squibb Company.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Trader Talk

Add Your Comment